Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study.
Journal: Expert opinion on biological therapy
Published: September 01, 2026
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials.
Journal: Human vaccines & immunotherapeutics
Published: May 05, 2026
Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study.
Journal: Journal of neurology
Published: February 12, 2026
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.
Journal: Advances in therapy
Published: December 16, 2025
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study.
Journal: European journal of neurology
Published: October 15, 2025
Validation and Reliability of the Thai Pediatric Charcot-Marie-Tooth Quality of Life Outcome Measure.
Journal: Journal of the peripheral nervous system : JPNS
Published: May 21, 2025
Psychometric analysis of the Neuro-QoL Fatigue in generalized Myasthenia Gravis (gMG) using data from a phase 3 trial.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: May 15, 2025
Nipocalimab Dose Selection in Generalized Myasthenia Gravis.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 31, 2025
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Journal: The Lancet. Neurology
Published: September 06, 2024
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study
Journal: Neurology
Published: January 02, 2024
Parent-proxy pediatric CMT quality of life outcome measure: Validation of the Italian version.
Journal: Journal of the peripheral nervous system : JPNS
Published: October 26, 2023
Validation of the parent-proxy version of the pediatric Charcot-Marie-Tooth disease quality of life instrument for children aged 0-7 years.
Journal: Journal of the peripheral nervous system : JPNS
Published: March 10, 2023
Last Updated: 09/26/2026